SXCross
Oct 26, 9:29 AM
$OGEN ONP-002: Best-in-class, proven safe, Phase 2 active.
The Asset
ONP-002 is a novel intranasal neurosteroid that addresses the underlying biological processes of brain injuries—rather than merely treating their symptoms. It is administered via a patented intranasal delivery system, reaching the brain directly through the olfactory nerve. Once there, it reduces swelling and inflammation, preserves the integrity of the blood-brain barrier, and promotes cell survival.
In Phase 1 clinical trials, the safety and tolerability of ONP-002 were demonstrated in 40 patients, with no serious adverse events reported. ONP-002 is currently being evaluated in an active, randomized, placebo-controlled Phase 2a clinical trial, which is enrolling patients in Australia.
1 replies
